Tisotumab vedotin effective in recurrent cervical cancer
IF 81.1
1区 医学
Q1 ONCOLOGY
引用次数: 0
替索单抗维多汀对复发性宫颈癌有效
复发性晚期和/或转移性宫颈癌患者的预后通常较差，可供选择的治疗方案有限。现在，innovaTV 301 III 期试验的数据证明了组织因子靶向抗体药物共轭物 tisotumab vedotin 在这种情况下的疗效。研究人员随机分配（1:1）502名既往接受过1线（62.8%）或2线（36.8%）治疗的晚期和/或转移性宫颈癌患者接受替索单抗维多汀与研究者选择的化疗（包括托泊替康、维诺雷滨、吉西他滨、伊立替康或培美曲塞）。总生存期（OS）是主要终点。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
